Wellness Center USA (WCUI) 10-Q 15 May 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	6 Months Ended
	Mar. 31, 2018shares
Document And Entity Information
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	1,516,887
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	92,879,384
Trading Symbol	WCUI
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Sep. 30, 2017
Current Assets
Cash	$ 40,413	$ 29,369
Accounts receivable		24,999
Inventories	12,057	12,335
Prepaid expenses and other current assets	2,213	1,751
Total Current Assets	54,683	68,454
Property and equipment, net	3,148	5,126
Other assets	16,760	16,760
Total Other Assets	19,908	21,886
TOTAL ASSETS	74,591	90,340
Current Liabilities
Accounts payable and accrued expenses	376,641	203,367
Accrued payroll - officers	51,381	13,440
Deferred revenue	49,598	55,098
Convertible notes payable	130,721	49,884
Loans payable from officers and shareholders	227,500	59,000
Total Current Liabilities	835,841	380,789
Shareholders' Deficit
Common stock, par value $0.001, 185,000,000 shares authorized; 92,879,384 and 90,284,916 shares issued and outstanding, respectively	93,066	90,285
Additional paid-in capital	19,841,209	19,069,211
Accumulated deficit	(20,310,695)	(19,132,557)
Total Wellness Center USA shareholders' equity (deficit)	(376,420)	26,939
Non-controlling interest	(384,830)	(317,388)
Total Shareholder's deficit	(761,250)	(290,449)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 74,591	$ 90,340

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2018	Sep. 30, 2017
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	185,000,000	185,000,000
Common stock, shares, issued	92,879,384	90,284,916
Common stock, shares, outstanding	92,879,384	90,284,916

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Sales:
Trade	$ 20,500	$ 120,100	$ 36,000	$ 209,100
Consulting services	20,750	14,125	31,750	28,250
Total Sales	41,250	134,225	67,750	237,350
Cost of goods sold	17,666	53,407	34,658	113,907
Gross profit	23,584	80,818	33,092	123,443
Operating expenses	561,317	609,624	895,480	1,026,187
Loss from operations	(537,733)	(528,806)	(862,388)	(902,744)
Other income (expenses)
Amortization of debt discount	(65,790)		(135,837)
Gain on extinguishment of debt		288,777		288,777
Loss on modification of conversion price on convertible note payable	(158,400)		(158,400)
Loss on modification of exercise price on warrants in connection with convertible note payable	(5,445)		(5,445)
Financing costs	(70,422)		(70,422)
Interest expense	(9,788)		(13,088)
Total other income (expenses)	(309,845)	288,777	(383,192)	288,777
LOSS FROM CONTINUING OPERATIONS	(847,578)	(240,029)	(1,245,580)	(613,967)
DISCONTINUED OPERATIONS
Loss from discontinued operations		(29,361)		(70,923)
NET LOSS	(847,578)	(269,390)	(1,245,580)	(684,890)
Net loss (gain) attributable to non-controlling interest	21,473	(5,430)	67,442	1,098
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	$ (826,105)	$ (274,820)	$ (1,178,138)	$ (683,792)
BASIC AND DILUTED LOSS PER SHARE	$ (0.01)	$ 0	$ (0.01)	$ (0.01)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	91,551,485	84,644,460	91,414,889	82,814,207

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 6 months ended Mar. 31, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2017	$ 90,285	$ 19,069,211	$ (19,132,557)	$ 26,939	$ (317,388)	$ (290,449)
Balance, shares at Sep. 30, 2017	90,284,916
Exercise of stock warrants	$ 1,407	169,507		170,914		$ 170,914
Exercise of stock warrants, shares	1,407,619
Fair value of common stock issued for services	$ 150	26,550		26,700		$ 26,700
Fair value of common stock issued for services, shares	150,000
Shares issued upon conversions of note payable	$ 737	54,263		55,000		55,000
Shares issued upon conversions of note payable, shares	550,000
Fair value of vested stock options		137,898		137,898		137,898
Fair value of common stock issued in connection with convertible note payable	$ 487	69,935		70,422		70,422
Fair value of common stock issued in connection with convertible note payable, shares	486,849
Discount on convertible note payable due to beneficial conversion and warrants		150,000		150,000		150,000
Discount on convertible note payable due to beneficial conversion and warrants, shares
Loss on modification of conversion price on convertible note payable		158,400		158,400		158,400
Loss on modification of exercise price on warrants in connection with convertible note payable		5,445		5,445		5,445
Net loss			(1,178,138)	(1,178,138)	(67,442)	(1,245,580)
Balance at Mar. 31, 2018	$ 93,066	$ 19,841,209	$ (20,310,695)	$ (376,420)	$ (384,830)	$ (761,250)
Balance, shares at Mar. 31, 2018	92,879,384

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash Flows from Operating Activities
Net loss	$ (1,245,580)	$ (684,890)
Adjustments to reconcile net loss to net cash used in operating activities
Loss from discontinued operations		70,923
Depreciation expense	1,978	5,402
Amortization of debt discount	135,837
Gain on extinguishment of debt		(288,777)
Fair value of common shares issued for services	26,700	26,000
Fair value of stock options issued for services	137,898	178,068
Loss on modification of conversion price on convertible note payable	158,400
Loss on modification of exercise price on warrants in connection with convertible note payable	5,445
Fair value of common stock issued in connection with convertible note payable	70,422
(Increase) Decrease in:
Accounts receivable	24,999	(70,000)
Inventories	278	66,787
Prepaid expenses and other current assets	(462)	24,613
(Decrease) Increase in:
Accounts payable and accrued expenses	173,274	(25,500)
Accrued payroll taxes		20,506
Accrued payroll - officers	37,941	25,371
Deferred revenue	(5,500)	(24,826)
Net cash used in operating activities from continuing operations	(478,370)	(676,323)
Net cash used in operating activities from discontinued operations		(6,489)
Net cash used in operating activities	(478,370)	(682,812)
Cash Flows from Investing Activities
Purchases of property and equipment		(546)
Net cash used in investing activities from continuing operations		(546)
Net cash used in investing activities from discontinued operations		(1,704)
Net cash used in investing activities		(2,250)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	179,000	30,000
Repayment of loans payable from officers and shareholders	(10,500)
Proceeds from convertible note payable	150,000
Repayment of advances from related party		(2,000)
Proceeds from the sale of common stock and warrants		424,600
Exercise of stock warrants	170,914	428,015
Net cash provided by financing activities	489,414	880,615
Net increase in cash	11,044	195,553
Cash beginning of period	29,369	81,749
Cash end of period	40,413	277,302
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Debt discount on convertible note payable	150,000
Conversion of convertible note payable into common shares	55,000
Non-controlling interest's share in losses of a subsidiary	$ 67,442	$ 1,098

Organization and Basis of Prese

Organization and Basis of Presentation	6 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”), National Pain Centers, Inc. (“NPC”), and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. On August 11, 2017, the Company entered into an agreement to sell 100% of the issued and outstanding shares of NPC, which has been accounted for as a discontinued operation on the condensed consolidated statement of operations for the three months ended March 31, 2017. See Note 3 for details relating to the sale. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Basis of Presentation of Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the six months ended March 31, 2018 are not necessarily indicative of the results that may be expected for the year ending September 30, 2018. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the six months ended March 31, 2018, the Company incurred a net loss from continuing operations of $1,245,580 and used cash in operations from continuing operations of $478,370 and had a shareholders’ deficit of $761,250 as of March 31, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2017 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern. At March 31, 2018, the Company had cash on hand in the amount of $40,413. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the six months ended March 31, 2018, the Company received $489,414 through debt financing and the exercise of stock warrants. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50% Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the six months ended March 31, 2018 and 2017, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At March 31, 2018 and 2017, the dilutive impact of outstanding stock options for 8,847,500 and 6,147,500 shares, respectively, and outstanding warrants for 59,096,084 and 63,741,253 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. In addition to the aforementioned general policy, the following are the specific revenue recognition policies for each major category of revenue: (i) Sale of products : (ii) Consulting services: Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at March 31, 2018 and 2017 was $49,598 and $55,098, respectively. Non-controlling Interest Non-controlling interest represents the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 3 – DISCONTINUED OPERATIONS On August 11, 2017, the Company entered into an agreement with Dr. Jay Joshi to sell 100% of the issued and outstanding shares of NPC Inc. (“NPC”) to Dr. Joshi. As part of the agreement, Dr. Joshi and NPC released the Company from any and all liabilities, claims and obligations of the Company in favor of Dr. Joshi or NPC and arising from or relating to the operation of the NPC business. Also as part of the agreement, Dr. Joshi’s employment agreement with NPC was terminated and all assets and liabilities of NPC were transferred to Dr. Joshi as of the date of the agreement, including $365,459 of accrued compensation and shareholder advances owed to Dr. Joshi by NPC. The Company agreed to sell NPC to Dr. Joshi so that it could focus on its other business segments, PSI and Stealth Mark, which are technology companies, while NPC was a service business. Further, the elimination of the underlined NPC liabilities to Dr. Joshi will significantly improve Wellness Center Inc.’s financial position. As part of the agreement, the Company agreed to issue Dr. Joshi stock options to purchase 500,000 shares of its common stock with an exercise price of $0.25 per share. Dr. Joshi continued to serve on the Company’s board of directors until February 5, 2018. During the year ended September 30, 2017, the Company recorded a $252,508 gain relating to this transaction. Components of the statement of operations relating to NPC for the three and six months ended March 31, 2017, were as follows: Three Months Ended Six Months Ended March 31, 2017 March 31, 2017 Total Sales $ 40,000 $ 77,402 Operating expenses 69,361 148,325 Loss from discontinued operations $ (29,361 ) $ (70,923 )

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	6 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 4 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS At September 30, 2017, loans payable from officers and shareholders of $59,000 consisted of two unsecured note agreements issued in 2014 totaling to $9,000, and two short-term unsecured loans issued in fiscal 2017 totaling to $50,000. The loans issued in 2014 have no stated interest rate and are due on demand. The loans issued in 2017 have an interest rate of eight percent per annum and are due one year from the date of issuance. During the six months ended March 31, 2018, the Company borrowed $179,000 under nine short-term unsecured loans. The loans have an interest rate of eight percent and are due one year from the date of issuance. During the six months ended March 31, 2018, the Company repaid $10,500 of the loans payable. As of March 31, 2018, loans payable from officers and shareholders of $227,500 were outstanding.

Convertible Notes Payable Agree

Convertible Notes Payable Agreements	6 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Convertible Notes Payable Agreements	NOTE 5 – CONVERTIBLE NOTES PAYABLE AGREEMENTS March 31, 2018 September 30, 2017 Convertible note payable (a) $ 110,000 $ 165,000 Convertible note payable (b) 165,000 - Debt discount – unamortized balance (144,279 ) (115,116 ) Convertible notes payable, net $ 130,721 $ 49,884 (a) In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on a probability affected Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. During the six months ended March 31, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at March 31, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. The Company recorded an expense of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of expense the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the six months ended March 31, 2018, the individual converted $55,000 of the convertible note payable into 550,000 shares of the Company’s common stock. (b) On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, and the aggregate amount of $150,000 relating to the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the three and six months ended March 31, 2018, the Company amortized $20,721 of debt discount, leaving an unamortized balance of $144,279 at March 31, 2018. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 300,000 shares of common stock granted at the date issuance.

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Shareholders' Deficit	NOTE 6 – SHAREHOLDERS’ DEFICIT Common shares issued for Services During the six months ended March 31, 2018, the Company issued 150,000 shares of its common stock valued at $26,700 for services provided by accounting and PSI consultants. The shares were valued at the trading price of the common stock at the date of issuance. Common shares issued in connection with Convertible Notes Payable During the six months ended March 31, 2018, the Company issued 486,849 shares of its common stock in connection with the issuance of convertible notes payable and also issued 550,000 shares upon the conversion of the notes payable (see Note 5). Stock Options On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000 (see Note 9). On January 1, 2018, the Company entered into employment agreements with three employees of SCI. Under the agreements, the Company issued options to purchase a combined total of 1,775,000 shares of its common stock with a fair value of $289,890. The options are exercisable over a term of five years, with an exercise price of $0.19. The Company valued the options using a Black-Scholes option pricing model. A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months. During the three and six months ended March 31, 2018, the Company recorded $110,498 of stock compensation for the value of the options and as of March 31, 2018, unvested compensation of $179,392 remained that will be amortized over the remaining vesting period. Further, beginning on January 1, 2018, they will be granted additional stock options to purchase up to an aggregate total of 250,000 shares of the Company’s common stock each quarter. The options are exercisable over a five year period, are issuable on the last day of each quarter ending and vest immediately on the date of grant. All options accelerate and become fully vested upon the sale or change of control of the Company. During the six months ended March 31, 2018, the Company issued options to purchase 250,000 shares of its common stock to the employees with an exercise price of $0.13 per share. During the six months ended March 31, 2018, the Company valued the options using a Black-Scholes option pricing model and recorded $27,400 of stock compensation for the value of the options vested. The assumptions used for options granted during the six months ended March 31, 2018 are as follows: Exercise price $ 0.13 - 0.19 Expected dividends - Expected volatility 123.8% - 130.2 % Risk free interest rate 2.01% - 2.18 % Expected life of options 2.5 The table below summarizes the Company’s stock option activities for the three months ended March 31, 2018: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Grant Balance, September 30, 2017 6,822,500 $ 0.10 - 2.00 $ 0.51 $ 1,865,628 Granted 2,025,000 0.13 - 0.19 0.18 317,971 Cancelled - - - - Exercised - - - - Expired - - - - Balance, March 31, 2018 8,847,500 $ 0.10 – 2.00 $ 0.43 $ 2,183,599 Vested and exercisable, March 31, 2018 7,747,500 $ 0.10 – 2.00 $ 0.43 $ 2,003,527 Unvested, March 31, 2018 1,100,000 $ 0.19 $ 0.19 $ 180,072 The aggregate intrinsic value for option shares outstanding at March 31, 2018 was $13,438. The following table summarizes information concerning outstanding and exercisable options as of March 31, 2018: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.10 - 0.39 5,325,000 3.72 $ 0.18 4,225,000 3.72 $ 0.18 0.40 - 0.99 2,122,500 1.05 0.40 2,122,500 1.05 0.40 1.00 - 1.99 750,000 2.75 1.00 750,000 2.75 1.00 2.00 650,000 2.75 2.00 650,000 2.75 2.00 $ 0.01 - 2.00 8,847,500 2.93 $ 0.43 7,747,500 2.93 $ 0.43 As of March 31, 2018, there were 21,152,500 shares of stock options remaining available for issuance under the 2010 Plan. Stock Warrants During the six months ended March, 31, 2018, the Company issued warrants to purchase 660,000 shares with an exercise price of $0.20 per share in connection with the issuance of a convertible note payable (see Note 5). The warrants expire five years from the date of grant. During the six months ended March, 31, 2018, warrants to purchase 1,407,619 shares of the Company’s common stock were exercised for $170,914. The table below summarizes the Company’s warrants activities for the three months ended March 31, 2018: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 660,000 0.20 0.20 132,000 Cancelled - - - - Exercised (1,407,619 ) 0.12 – 0.15 0.12 - Expired (4,317,602 ) 0.30 – 0.45 0.43 - Balance, March 31, 2018 59,096,084 $ 0.12 - 1.00 $ 0.22 $ 2,283,219 Vested and exercisable, March 31, 2018 59,096,084 $ 0.12 - 1.00 $ 0.22 $ 2,283,219 Unvested, March 31, 2018 - $ - $ - $ - The aggregate intrinsic value for warrant shares outstanding March 31, 2018 was $95,733. The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2018: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 43,183,441 2.61 $ 0.15 43,183,441 2.61 $ 0.15 0.21 – 0.49 11,412,905 2.13 0.32 11,412,905 2.13 0.32 0.50 – 1.00 4,499,738 0.38 0.75 4,499,738 0.38 0.75 $ 0.12 – 1.00 59,096,084 2.35 $ 0.22 59,096,084 2.35 $ 0.22

Segment Reporting

Segment Reporting	6 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Reporting	NOTE 7 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. During the year ended September 30, 2017, the Company discontinued operations of its NPC segment (see Note 3). The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Wellness Center USA, Inc. Assets By Segments March 31, 2018 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 24,884 $ 1,003 $ 14,526 $ 40,413 Accounts receivable - - - - Inventories - - 12,057 12,057 Prepaid expenses and other current assets - - 2,213 2,213 Total current assets 24,884 1,003 28,796 54,683 Property and equipment, net - - 3,148 3,148 Other assets 15,000 1,760 - 16,760 Total other assets 15,000 1,760 3,148 19,908 TOTAL ASSETS $ 39,884 $ 2,763 $ 31,944 $ 74,591 Wellness Center USA, Inc. Operations by Segments For the Six Months Ended March 31, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - - $ 36,000 $ 36,000 Consulting services - - 31,750 31,750 Total Sales - - 67,750 67,750 Cost of goods sold - - 34,658 34,658 Gross profit - - 33,092 33,092 Operating expenses 397,108 135,934 362,438 895,480 Loss from operations $ (397,108 ) $ (135,934 ) $ (329,346 ) $ (862,388 ) Wellness Center USA, Inc. Operations by Segments For the Six Months Ended March 31, 2017 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 196,000 $ 13,100 $ 209,100 Consulting services - - 28,250 28,250 Total Sales - 196,000 41,350 237,350 Cost of goods sold - 75,117 38,790 113,907 Gross profit - 120,883 2,560 123,443 Operating expenses 568,610 157,039 300,538 1,026,187 Loss from operations $ (568,610 ) $ (36,156 ) $ (297,978 ) $ (902,744 )

Legal Matters

Legal Matters	6 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Legal Matters	NOTE 8 – LEGAL MATTERS The Company is periodically engaged in legal proceedings arising from and relating to its business operations. We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations. In May, 2017, the Staff issued a Wells Notice stating its preliminary determination to recommend an enforcement action against the Company and our CEO, Mr. Kandalepas, based on possible violations of Section 17(a) of the Securities Act, Sections 15 (a) and 10(b) of the Exchange Act, and Rule 10b-5 thereunder. The Staff would allege, among other things, that periodic reports issued during 2013 and 2014 were misleading because they failed to disclose or mischaracterized as “salary”, “prepayments” or “loans,” several payments totaling $450,000 made to our CEO during those years without prior Board approval; that two press releases issued in 2015 touted shipments of several Psoria-Light devices that were not closed sales; and that we used an unregistered broker-dealer to identify and solicit potential investors during 2013, 2015 and 2017. Subsequent discussions resulted in our submission of an Offer of Settlement (“Settlement”) through an administrative cease and desist action on November 17, 2017, which was accepted by the SEC on April 12, 2018. Pursuant to the Settlement, we neither admit nor deny any of the proposed allegations, but are enjoined from violating the above-referenced Sections and Rule. The Settlement imposes no financial penalties or sanctions against the Company. On April 13, 2018, the SEC filed a separate complaint against our CEO in the U.S. District Court for the Northern District of Illinois. It asserts the allegations noted above, as well as allegations that he manipulated the price of company shares through undisclosed trading, realizing more than $130,000 from such trading. The SEC seeks a permanent injunction, disgorgement including prejudgment interest, a civil penalty, an officer-and-director bar, and a penny stock bar. Mr. Kandalepas intends to contest the allegations against him. He has voluntarily resigned as an officer and director. He has agreed to provide transition services to Calvin R. O’Harrow and Roy M. Harsch, who have been appointed to serve as CEO and Chairman, respectively. Mr. Kandalepas will remain with the Company to serve as Executive Director of Corporate Business Development.

Subsequent Events

Subsequent Events	6 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 9 – SUBSEQUENT EVENTS Subsequent to March 31, 2018, the Company borrowed $80,000 from Directors, an officer and a shareholder. Of these loans, $60,000, along with loans payable of $188,500 outstanding at March 31, 2018, were converted into 1,962,498 shares of common stock. In connection with the conversion of the loans payable, the Company issued warrants to purchase 3,925,002 shares of common stock. The warrants expire five years from the date of grant and have exercise prices of $0.14 and $0.18 per share. An aggregate total of $70,000 of a convertible note payable was converted into 700,000 shares of the Company’s common stock. The Company granted 500,000 shares of its common stock to consultants for services provided. The fair value of the shares on the dates of grant was $70,000. In April 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the 2010 Option Plan from 7,500,000 to 30,000,000, effective January 1, 2018 (see Note 6). In April 2018, the Company granted options to purchase 11,980,000 shares of its common stock to its officers and directors with a fair value of approximately $1,400,000. The options have an exercise price of $0.14 per share and expire five years from the date of grant. A total of 1,230,000 shares vested upon grant and 10,750,000 shares will vest ratably on a monthly basis over 36 months. In May 2018, the Company received $50,000 from the sale of 333,333 shares of its common stock. In connection with the sale, the Company issued warrants to the shareholders to purchase 666,667 shares of the Company’s common stock. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. In May 2018, the Board approved the permanent appointment of Roy M. Harsch as Chairman of the Board of Directors and Calvin O’Harrow as Chief Executive Officer.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50%
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) per Share Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the six months ended March 31, 2018 and 2017, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At March 31, 2018 and 2017, the dilutive impact of outstanding stock options for 8,847,500 and 6,147,500 shares, respectively, and outstanding warrants for 59,096,084 and 63,741,253 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. In addition to the aforementioned general policy, the following are the specific revenue recognition policies for each major category of revenue: (i) Sale of products : (ii) Consulting services: Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at March 31, 2018 and 2017 was $49,598 and $55,098, respectively.
Non-controlling Interest	Non-controlling Interest Non-controlling interest represents the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance.
Stock-Based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50%

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Statement of Operations of Discontinued Operations	Components of the statement of operations relating to NPC for the three and six months ended March 31, 2017, were as follows: Three Months Ended Six Months Ended March 31, 2017 March 31, 2017 Total Sales $ 40,000 $ 77,402 Operating expenses 69,361 148,325 Loss from discontinued operations $ (29,361 ) $ (70,923 )

Convertible Notes Payable Agr19

Convertible Notes Payable Agreements (Tables)	6 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	March 31, 2018 September 30, 2017 Convertible note payable (a) $ 110,000 $ 165,000 Convertible note payable (b) 165,000 - Debt discount – unamortized balance (144,279 ) (115,116 ) Convertible notes payable, net $ 130,721 $ 49,884 (a) In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on a probability affected Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. During the six months ended March 31, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at March 31, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. The Company recorded an expense of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of expense the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the six months ended March 31, 2018, the individual converted $55,000 of the convertible note payable into 550,000 shares of the Company’s common stock. (b) On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, and the aggregate amount of $150,000 relating to the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the three and six months ended March 31, 2018, the Company amortized $20,721 of debt discount, leaving an unamortized balance of $144,279 at March 31, 2018. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 300,000 shares of common stock granted at the date issuance.

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	6 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Schedule of Assumptions Used for Options Granted	The assumptions used for options granted during the six months ended March 31, 2018 are as follows: Exercise price $ 0.13 - 0.19 Expected dividends - Expected volatility 123.8% - 130.2 % Risk free interest rate 2.01% - 2.18 % Expected life of options 2.5
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the three months ended March 31, 2018: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Grant Balance, September 30, 2017 6,822,500 $ 0.10 - 2.00 $ 0.51 $ 1,865,628 Granted 2,025,000 0.13 - 0.19 0.18 317,971 Cancelled - - - - Exercised - - - - Expired - - - - Balance, March 31, 2018 8,847,500 $ 0.10 – 2.00 $ 0.43 $ 2,183,599 Vested and exercisable, March 31, 2018 7,747,500 $ 0.10 – 2.00 $ 0.43 $ 2,003,527 Unvested, March 31, 2018 1,100,000 $ 0.19 $ 0.19 $ 180,072
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of March 31, 2018: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.10 - 0.39 5,325,000 3.72 $ 0.18 4,225,000 3.72 $ 0.18 0.40 - 0.99 2,122,500 1.05 0.40 2,122,500 1.05 0.40 1.00 - 1.99 750,000 2.75 1.00 750,000 2.75 1.00 2.00 650,000 2.75 2.00 650,000 2.75 2.00 $ 0.01 - 2.00 8,847,500 2.93 $ 0.43 7,747,500 2.93 $ 0.43
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the three months ended March 31, 2018: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 660,000 0.20 0.20 132,000 Cancelled - - - - Exercised (1,407,619 ) 0.12 – 0.15 0.12 - Expired (4,317,602 ) 0.30 – 0.45 0.43 - Balance, March 31, 2018 59,096,084 $ 0.12 - 1.00 $ 0.22 $ 2,283,219 Vested and exercisable, March 31, 2018 59,096,084 $ 0.12 - 1.00 $ 0.22 $ 2,283,219 Unvested, March 31, 2018 - $ - $ - $ -
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of March 31, 2018: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 43,183,441 2.61 $ 0.15 43,183,441 2.61 $ 0.15 0.21 – 0.49 11,412,905 2.13 0.32 11,412,905 2.13 0.32 0.50 – 1.00 4,499,738 0.38 0.75 4,499,738 0.38 0.75 $ 0.12 – 1.00 59,096,084 2.35 $ 0.22 59,096,084 2.35 $ 0.22

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Wellness Center USA, Inc. Assets By Segments March 31, 2018 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 24,884 $ 1,003 $ 14,526 $ 40,413 Accounts receivable - - - - Inventories - - 12,057 12,057 Prepaid expenses and other current assets - - 2,213 2,213 Total current assets 24,884 1,003 28,796 54,683 Property and equipment, net - - 3,148 3,148 Other assets 15,000 1,760 - 16,760 Total other assets 15,000 1,760 3,148 19,908 TOTAL ASSETS $ 39,884 $ 2,763 $ 31,944 $ 74,591
Schedule of Operations of Reportable Segments	Wellness Center USA, Inc. Operations by Segments For the Six Months Ended March 31, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - - $ 36,000 $ 36,000 Consulting services - - 31,750 31,750 Total Sales - - 67,750 67,750 Cost of goods sold - - 34,658 34,658 Gross profit - - 33,092 33,092 Operating expenses 397,108 135,934 362,438 895,480 Loss from operations $ (397,108 ) $ (135,934 ) $ (329,346 ) $ (862,388 ) Wellness Center USA, Inc. Operations by Segments For the Six Months Ended March 31, 2017 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 196,000 $ 13,100 $ 209,100 Consulting services - - 28,250 28,250 Total Sales - 196,000 41,350 237,350 Cost of goods sold - 75,117 38,790 113,907 Gross profit - 120,883 2,560 123,443 Operating expenses 568,610 157,039 300,538 1,026,187 Loss from operations $ (568,610 ) $ (36,156 ) $ (297,978 ) $ (902,744 )

Organization and Basis of Pre22

Organization and Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Aug. 11, 2017	Sep. 30, 2016
Entity incorporation, state country name			Nevada
Net loss from continuing operations	$ 847,578	$ 269,390	$ 1,245,580	$ 684,890
Net cash used in operating activities from continuing operations			478,370	676,323
Shareholders' deficit	761,250		761,250		$ 290,449
Cash on hand	$ 40,413	$ 277,302	40,413	277,302	$ 29,369		$ 81,749
Proceeds from debt financing and exercise of stock warrants			$ 489,414	$ 880,615
NPC Inc. [Member]
Ownership interest, percentage						100.00%

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017
Deferred revenue	$ 49,598	$ 55,098	$ 55,098
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share	8,847,500	6,147,500
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	59,096,084	63,741,253

Summary of Significant Accoun24

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	6 Months Ended
	Mar. 31, 2018
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield Inc. [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. (“PSI”)
State or other jurisdiction of incorporation or organization	The State of Florida
Date of incorporation or formation	Jun. 17, 2009
Date of acquisition/disposition	Aug. 24, 2012
Attributable interest	100.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. (“StealthCo”)
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Mar. 18, 2014
Attributable interest	100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. (“PDC”)
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Jan. 15, 2015
Attributable interest	50.00%

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - NPC Inc. [Member] - USD ($)	12 Months Ended
	Sep. 30, 2017	Aug. 11, 2017
Ownership interest, percentage		100.00%
Dr. Jay Joshi [Member]
Ownership interest, percentage		100.00%
Accrued compensation		$ 365,459
Number of stock options issued to purchase common stock		500,000
Common stock exercise price		$ 0.25
Gain relating to transaction	$ 252,508

Discontinued Operations - State

Discontinued Operations - Statement of Operations of Discontinued Operations (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Discontinued Operations and Disposal Groups [Abstract]
Total Sales		$ 40,000		$ 77,402
Operating expenses		69,361		148,325
Loss from discontinued operations		$ (29,361)		$ (70,923)

Loans Payable from Officers a27

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	6 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017	Sep. 30, 2014
Loans payable from officers and shareholders	$ 227,500		$ 59,000
Proceeds from short term debt	179,000	$ 30,000
Repayments of short term debt	$ 10,500
Two Short-term Unsecured Loans [Member]
Loans payable from officers and shareholders			$ 50,000
Debt instrument, interest rate, stated percentage			8.00%
Debt instrument, payment terms			due one year from the date of issuance.
Nine Short-Term Unsecured Loans [Member]
Debt instrument, interest rate, stated percentage	8.00%
Debt instrument, payment terms	due one year from the date of issuance.
Proceeds from short term debt	$ 179,000
Two Unsecured Note Agreements [Member]
Loans payable from officers and shareholders				$ 9,000
Debt instrument, interest rate, stated percentage				0.00%
Debt instrument, payment terms				due on demand

Convertible Notes Payable Agr28

Convertible Notes Payable Agreements - Schedule of Convertible Notes Payable (Details) - USD ($)		Mar. 31, 2018	Sep. 30, 2017
Debt discount - unamortized balance		$ (144,279)	$ (115,116)
Convertible note payable, net		130,721	49,884
Convertible Note Payable One [Member]
Convertible note payable	[1]	110,000	165,000
Convertible Note Payable Two [Member]
Convertible note payable	[2]	$ 165,000
[1]	In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.25 per share. The note matures in February 2018, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days’ prior written notice. On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on a probability affected Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. During the six months ended March 31, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at March 31, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. The Company recorded an expense of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of expense the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the six months ended March 31, 2018, the individual converted $55,000 of the convertible note payable into 550,000 shares of the Company’s common stock.
[2]	On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.10 per share. The note matures in October 2018, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days’ prior written notice. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the three and six months ended March 31, 2018, the Company amortized $20,721 of debt discount, leaving an unamortized balance of $144,279 at March 31, 2018. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 330,000 shares of common stock granted at the date issuance.

Convertible Notes Payable Agr29

Convertible Notes Payable Agreements - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Mar. 05, 2018	Feb. 28, 2018	Jul. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Sep. 30, 2017
Proceeds from convertible notes payable						$ 150,000
Number of common stock and warrants issued to purchase common shares				1,407,619		1,407,619
Debt instrument, unamortized discount				$ 144,279		$ 144,279		$ 115,116
Loss on modification of conversion price on convertible note payable				158,400		158,400
Loss on modification of exercise price on warrants in connection with convertible note payable				5,445		5,445
Convertible Note Payable Agreement One [Member]
Debt instrument, unamortized discount								$ 115,116
Fair value of warrants						$ 87,582
Volatility rate						139.98%
Risk-free rate						1.28%
Amortization of debt discount						$ 115,116
Conversion of debt into common stock						$ 55,000
Conversion of debt into common stock, shares						550,000
Convertible Note Payable Agreement One [Member] | Warrant [Member]
Stock price				$ 0.31		$ 0.31
Convertible Note Payable Agreement One [Member] | Individual [member]
Debt instrument, face amount			$ 165,000
Proceeds from convertible notes payable			$ 150,000
Number of restricted shares issued			165,000
Number of common stock and warrants issued to purchase common shares			330,000
Warrant term			5 years
Warrant exercise price			$ 0.50
Debt instrument interest rate			8.00%
Debt instrument, collateral			unsecured
Debt instrument, convertible, terms of conversion feature			convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.25 per share.
Debt instrument conversion price			$ 0.25
Debt instrument maturity date description			February 2,018
Closing price of the common stock			$ 0.31
Debt instrument, unamortized discount			$ 150,000
Intrinsic value of beneficial conversion features			94,704
Fair value of warrants			$ 55,296
Stock price		$ 0.12
Common stock issued, shares		186,849
Stock issuance cost		$ 22,422
Conversion of stock, shares converted	990,000
Stock conversion price	$ 0.16
Loss on modification of conversion price on convertible note payable	$ 158,400
Debt maturity date	Apr. 30, 2018
Convertible Note Payable Agreement One [Member] | Individual [member] | Maximum [Member]
Debt instrument conversion price	$ 0.25
Convertible Note Payable Agreement One [Member] | Individual [member] | Minimum [Member]
Debt instrument conversion price	$ 0.10
Convertible Note Payable Agreement One [Member] | Individual [member] | Warrant [Member]
Loss on modification of exercise price on warrants in connection with convertible note payable	$ 5,445
Convertible Note Payable Agreement One [Member] | Individual [member] | Warrant [Member] | Maximum [Member]
Debt instrument conversion price	$ 0.50
Convertible Note Payable Agreement One [Member] | Individual [member] | Warrant [Member] | Minimum [Member]
Debt instrument conversion price	$ 0.20
Convertible Note Payable Agreement Two [Member] | Individual [member]
Debt instrument, face amount	$ 165,000
Proceeds from convertible notes payable	$ 150,000
Number of restricted shares issued	300,000
Number of common stock and warrants issued to purchase common shares	660,000
Warrant term	5 years
Warrant exercise price	$ 0.20
Debt instrument interest rate	8.00%
Debt instrument, collateral	unsecured
Debt instrument, convertible, terms of conversion feature	convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.10 per share.
Debt instrument conversion price	$ 0.10
Debt instrument maturity date description	October 2,018
Debt instrument, unamortized discount	$ 94,968			$ 144,279		$ 144,279
Fair value of warrants	55,032
Amortization of debt discount						$ 20,721
Common stock issued, shares						300,000
Stock issuance cost						$ 48,000
Lender fee	15,000
Fair value of warrants and beneficial conversion features	$ 150,000

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($)	Jan. 02, 2018	Mar. 31, 2018	Mar. 31, 2018	Sep. 30, 2017
Number of stock issued for service, amount			$ 26,700
Common stock, shares authorized		185,000,000	185,000,000	185,000,000
Number options to purchase of common stock			2,025,000
Options exercisable term			2 years 11 months 4 days
Stock option exercise price per share	$ 0.13
Stock based compensation			$ 27,400
Unvested compensation		$ 179,392	179,392
Aggregate intrinsic value for option shares outstanding		$ 13,438	$ 13,438
Shares of stock options remaining available for issuance		21,152,500	21,152,500
Number of warrants issued to purchase common shares		1,407,619	1,407,619
Warrants to purchase shares of common stock, value		$ 170,914	$ 170,914
Aggregate intrinsic value for warrant shares outstanding		$ 95,733	$ 95,733
Stock Warrants [Member]
Number of warrants issued to purchase common shares		660,000	660,000
Warrant exercise price		$ 0.20	$ 0.20
Warrant expiration period			5 years
January 1, 2018 [Member]
Number options to purchase of common stock			675,000
Options Vesting description			A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months
Employment Agreement with Three Employees [Member]
Number options to purchase of common stock			250,000
Stock based compensation		$ 110,498	$ 110,498
Employment Agreement with Three Employees [Member] | January 1, 2018 [Member]
Number options to purchase of common stock			1,775,000
Fair value of stock options			$ 289,890
Options exercisable term			5 years
Stock option exercise price per share		$ 0.19	$ 0.19
Maximum [Member]
Number options to purchase of common stock	250,000
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized		7,500,000	7,500,000
2010 Non-Qualified Stock Option Plan [Member] | Minimum [Member]
Common stock, shares authorized		7,500,000	7,500,000
2010 Non-Qualified Stock Option Plan [Member] | Maximum [Member]
Common stock, shares authorized		30,000,000	30,000,000
Convertible Notes Payable [Member]
Numbers of shares issued			486,849
Number of stock converted into shares			550,000
PSI Consultants [Member]
Number of stock issued for service			150,000
Number of stock issued for service, amount			$ 26,700

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details)	6 Months Ended
	Mar. 31, 2018$ / shares
Expected dividends	0.00%
Expected volatility, minimum	123.80%
Expected volatility, maximum	130.20%
Risk free interest rate, minimum	2.01%
Risk free interest rate, maximum	2.18%
Expected life of options	2 years 6 months
Minimum [Member]
Exercise price	$ 0.13
Maximum [Member]
Exercise price	$ 0.19

Shareholders' Equity - Schedu32

Shareholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)	Jan. 02, 2018	Mar. 31, 2018
Number of Option Shares Outstanding, Number, Beginning Balance		6,822,500
Number of Option Shares Outstanding, Granted		2,025,000
Number of Option Shares Outstanding, Cancelled
Number of Option Shares Outstanding, Exercised
Number of Option Shares Outstanding, Expired
Number of Option Shares Outstanding, Number, Ending Balance		8,847,500
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance		7,747,500
Number of Option Shares Outstanding, Unvested, Ending Balance		1,100,000
Weighted Average Exercise Price, Number, Beginning Balance		$ 0.51
Weighted Average Exercise Price, Granted		0.18
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance		0.43
Weighted Average Exercise Price, Vested and exercisable, Ending Balance		0.43
Weighted Average Exercise Price, Unvested, Ending Balance		$ 0.19
Fair Value at Date of Grant, Number, Beginning Balance		$ 1,865,628
Fair Value at Date of Grant, Granted		317,971
Fair Value at Date of Grant, Cancelled
Fair Value at Date of Grant, Exercised
Fair Value at Date of Grant, Expired
Fair Value at Date of Grant, Number, Ending Balance		2,183,599
Fair Value at Date of Grant, Vested and exercisable, Ending Balance		2,003,527
Fair Value at Date of Grant, Unvested, Ending Balance		$ 180,072
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance		$ 0.10
Weighted Average Exercise Price, Granted		0.13
Weighted Average Exercise Price, Number, Ending Balance		0.10
Weighted Average Exercise Price, Vested and exercisable, Ending Balance		0.10
Maximum [Member]
Number of Option Shares Outstanding, Granted	250,000
Weighted Average Exercise Price, Number, Beginning Balance		2
Weighted Average Exercise Price, Granted		0.19
Weighted Average Exercise Price, Number, Ending Balance		2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance		$ 2

Shareholders' Equity - Schedu33

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	6 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Range of Exercise Prices, Lower Limit	$ 0.01
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	8,847,500	6,822,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 11 months 4 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.43	$ 0.51
Number of Options, Exercisable, Number	7,747,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 11 months 4 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.43
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.10
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	5,325,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	3 years 8 months 19 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.18
Number of Options, Exercisable, Number	4,225,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	3 years 8 months 19 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.18
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	$ 0.99
Number of Options, Outstanding, Number	2,122,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 18 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Options, Exercisable, Number	2,122,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 18 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	$ 1.99
Number of Options, Outstanding, Number	750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 9 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 1
Number of Options, Exercisable, Number	750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 9 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit	$ 2
Number of Options, Outstanding, Number	650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	2 years 9 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 2
Number of Options, Exercisable, Number	650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	2 years 9 months
Number of Options, Exercisable, Weighted Average Exercise Price	$ 2

Shareholders' Equity - Schedu34

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member]	6 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Number of Warrant Shares Outstanding, Number, Beginning Balance | shares	64,161,304
Number of Warrant Shares Outstanding, Granted | shares	660,000
Number of Warrant Shares Outstanding, Cancelled | shares
Number of Warrant Shares Outstanding, Exercised | shares	(1,407,619)
Number of Warrant Shares Outstanding, Expired | shares	(4,317,602)
Number of Warrant Shares Outstanding, Number, Ending Balance | shares	59,096,084
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance | shares	59,096,084
Number of Warrant Shares Outstanding, Unvested, Ending Balance | shares
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.24
Weighted Average Exercise Price, Granted	0.20
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised	0.12
Weighted Average Exercise Price, Expired	0.43
Weighted Average Exercise Price, Number, Ending Balance	0.22
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.22
Weighted Average Exercise Price, Unvested, Ending Balance
Fair Value at Date of Issuance, Number, Beginning Balance | $	$ 2,151,219
Fair Value at Date of Issuance, Granted | $	132,000
Fair Value at Date of Issuance, Cancelled | $
Fair Value at Date of Issuance, Exercised | $
Fair Value at Date of Issuance, Expired | $
Fair Value at Date of Issuance, Number, Ending Balance | $	2,283,219
Fair Value at Date of Issuance, Vested and exercisable, Ending Balance | $	2,283,219
Fair Value at Date of Issuance, Unvested, Ending Balance | $
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.12
Weighted Average Exercise Price, Exercised	0.12
Weighted Average Exercise Price, Expired	0.30
Weighted Average Exercise Price, Number, Ending Balance	0.12
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.12
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	1
Weighted Average Exercise Price, Exercised	0.15
Weighted Average Exercise Price, Expired	0.45
Weighted Average Exercise Price, Number, Ending Balance	1
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 1

Shareholders' Equity - Schedu35

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	6 Months Ended
	Mar. 31, 2018	Sep. 30, 2017
Range of Exercise Prices, Lower Limit	$ 0.01
Range of Exercise Prices, Upper Limit	2
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.10
Range of Exercise Prices, Upper Limit	0.39
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	0.99
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	1.99
Warrant [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 1
Number of Warrants, Outstanding, Number	59,096,084	64,161,304
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 4 months 6 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.22	$ 0.24
Number of Warrants, Exercisable, Number	59,096,084
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 4 months 6 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.22
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	43,183,441
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 7 months 10 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	43,183,441
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 7 months 10 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.49
Number of Warrants, Outstanding, Number	11,412,905
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 1 month 16 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.32
Number of Warrants, Exercisable, Number	11,412,905
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 1 month 16 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.32
Warrant [Member] | Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	0.50
Range of Exercise Prices, Upper Limit	$ 1
Number of Warrants, Outstanding, Number	4,499,738
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	4 months 17 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.75
Number of Warrants, Exercisable, Number	4,499,738
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	4 months 17 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.75

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Mar. 31, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016
Cash	$ 40,413	$ 29,369	$ 277,302	$ 81,749
Accounts receivable		24,999
Inventories	12,057	12,335
Prepaid expenses and other current assets	2,213	1,751
Total current assets	54,683	68,454
Property and equipment, net	3,148	5,126
Other assets	16,760	16,760
Total other assets	19,908	21,886
TOTAL ASSETS	74,591	$ 90,340
Corporate [Member]
Cash	24,884
Accounts receivable
Inventories
Prepaid expenses and other current assets
Total current assets	24,884
Property and equipment, net
Other assets	15,000
Total other assets	15,000
TOTAL ASSETS	39,884
Medical Devices [Member]
Cash	1,003
Accounts receivable
Inventories
Prepaid expenses and other current assets
Total current assets	1,003
Property and equipment, net
Other assets	1,760
Total other assets	1,760
TOTAL ASSETS	2,763
Authentication and Encryption [Member]
Cash	14,526
Accounts receivable
Inventories	12,057
Prepaid expenses and other current assets	2,213
Total current assets	28,796
Property and equipment, net	3,148
Other assets
Total other assets	3,148
TOTAL ASSETS	$ 31,944

Segment Reporting - Schedule 37

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017
Trade	$ 20,500	$ 120,100	$ 36,000	$ 209,100
Consulting services	20,750	14,125	31,750	28,250
Total Sales	41,250	134,225	67,750	237,350
Cost of goods sold	17,666	53,407	34,658	113,907
Gross profit	23,584	80,818	33,092	123,443
Operating expenses	561,317	609,624	895,480	1,026,187
Loss from operations	$ (537,733)	$ (528,806)	(862,388)	(902,744)
Employment Agreement with Three Employees [Member]
Trade			36,000
Consulting services			31,750
Total Sales			67,750
Cost of goods sold			34,658
Gross profit			33,092
Operating expenses			895,480
Loss from operations			(862,388)
Corporate [Member]
Trade
Consulting services
Total Sales
Cost of goods sold
Gross profit
Operating expenses			397,108	568,610
Loss from operations			(397,108)	(568,610)
Medical Devices [Member]
Trade				196,000
Consulting services
Total Sales				196,000
Cost of goods sold				75,117
Gross profit				120,883
Operating expenses			135,934	157,039
Loss from operations			(135,934)	(36,156)
Authentication and Encryption [Member]
Trade			36,000	13,100
Consulting services			31,750	28,250
Total Sales			67,750	41,350
Cost of goods sold			34,658	38,790
Gross profit			33,092	2,560
Operating expenses			362,438	300,538
Loss from operations			$ (329,346)	$ (297,978)

Legal Matters (Details Narrativ

Legal Matters (Details Narrative) - CEO [Member]	6 Months Ended
	Mar. 31, 2018USD ($)
Total payments to employee	$ 450,000
Maximum [Member]
Trading, realized amount	$ 130,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	6 Months Ended
	Apr. 30, 2018	Mar. 31, 2018	Mar. 31, 2018	May 30, 2018	Sep. 30, 2017
Warrants to purchase shares		1,407,619	1,407,619
Value of stock			$ 26,700
Common stock, shares authorized		185,000,000	185,000,000		185,000,000
Exercise price of options			$ 0.18
Minimum [Member]
Exercise price of options			0.13
Maximum [Member]
Exercise price of options			$ 0.19
Subsequent Event [Member]
Due from directors, officer and shareholder		$ 80,000	$ 80,000
Loans payable		$ 60,000	60,000
Debt instrument, amount converted			$ 188,500
Debt conversion into shares			1,962,498
Warrants to purchase shares		3,925,002	3,925,002
Warrants term			5 years
Stock issued during services			500,000
Value of stock			$ 70,000
Options granted to purchase shares	11,980,000
Fair value of options granted	$ 1,400,000
Exercise price of options	$ 0.14
Options term	5 years
Shares vested upon grants	1,230,000
Subsequent Event [Member] | May 2018 [Member]
Warrants to purchase shares				666,667
Exercise price of options		$ 0.18
Amount received on sale of stock		$ 50,000
Sale of shares of common stock		333,333
Subsequent Event [Member] | 36 Months [Member]
Shares vested upon grants	10,750,000
Subsequent Event [Member] | Minimum [Member]
Warrants exercise price		$ 0.14	$ 0.14
Subsequent Event [Member] | Minimum [Member] | 2010 Option Plan [Member]
Common stock, shares authorized	7,500,000
Subsequent Event [Member] | Maximum [Member]
Warrants exercise price		$ 0.18	$ 0.18
Subsequent Event [Member] | Maximum [Member] | 2010 Option Plan [Member]
Common stock, shares authorized	30,000,000